| CAS NO: | 603-00-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| Molecular Weight (MW) | 238.25 |
|---|---|
| Formula | C10H14N4O3 |
| CAS No. | 603-00-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO:>10 mM |
| Water: | |
| Ethanol: | |
| Solubility (In vivo) | |
| Synonyms | Monophylline, Spasmolysin |
| SMILES Code | O=C(N1C)N(C)C2=C(N(CC(O)C)C=N2)C1=O |
| In Vitro | In vitro activity: Proxyphylline has strong vasodilatory and cardiac stimulatory effects. It produces an increase in the coronary flow associated with a definite positive inotropic effect. Proxyphylline inhibits tracheal PDE-activity and half-maximum relaxation of tracheal smooth muscle is obtained with 100 μg/mL proxyphylline. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Proxyphylline exhibits bronchodilatory effect in a double-blind cross-over study, it inhibits cAMP and cGMP hydrolysis in human lung tissue. The apparent inhibition constant of proxyphylline is 0.06-0.7 mM at low cAMP concentrations and it is 1.0 mM at high cAMP concentration. |
| Animal model | |
| Formulation & Dosage | |
| References | Acta Pharmacol Toxicol (Copenh). 1982 Sep;51(3):250-2. |
m.cnreagent.com